-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $33

Benzinga·03/31/2026 10:55:01
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy and raises the price target from $30 to $33.